Clinical Trial

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-03.
Status change: Not Yet Recruiting → Recruiting 2026-03-02
Trial Details
NCT Number NCT07114315
Lead Sponsor Akeso
Conditions Pancreatic Cancer
Enrollment 160 participants
Start Date 2025-09-19
Primary Completion 2027-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-03